Needham & Company
-
Needham & Company Downgrades Targacept (TRGT) to Hold
-
Needham & Company Reiterates a 'Strong Buy' on Targacept (TRGT); 3Q11 Review; TC5214 Phase 3 Results in Depression Coming in November
-
Needham & Company Maintains a 'Buy' on Targacept (TRGT); Expect Continued Positive Results from AZN Collaboration
-
UPDATE - Needham & Company Upgraded Targacept (TRGT) to Strong Buy; Valuation Attractive after Distraction of AstraZeneca TC-5619 Option Decision
-
Needham & Company Upgrades Targacept (TRGT) to Strong Buy
-
Needham & Company Reiterates a 'Buy' on Targacept (TRGT); TC-5214 Registration Program Continues to Progress as Clinical Pipeline Expands to Inflammation
-
Needham & Company Reiterates a 'Buy' on Targacept (TRGT); 2011 Preview
-
Needham & Company Reiterates a 'Buy' on Targacept (TRGT); R&D Day Review.
-
Needham & Company Reiterates a 'Buy' on Targacept (TRGT); Update Ahead of R&D Day
-
Needham & Company Reiterates a 'Buy' on Targacept (TRGT); Believe There are Unrecognized Opportunities in Pipeline
-
Needham & Company Reiterates a 'Buy' on Targacept (TRGT); TC-5214 Phase 3 Depression Program Well Underway
-
Unusual 11 Mid-Day Movers 10/16: JOEZ, USEG, KNDI, TRGT Higher; CRYP, GNV, MTG, RDN Lower
-
Morning Movers 10/16: JOEZ, TRGT, KNDI, BCON, HUSA Higher; CRYP, MTG, NAVI, RDN, PMI, VMI Lower
-
Targacept (TRGT) Higher After Positive TC-5214 Trial For Major Depressive Disorder
-
Needham & Co Upgrades Targacept Inc. (TRGT) to Buy
-
Needham & Co Initiates Coverage on Targacept (TRGT) with a Hold; Valuation Call
-
Needham & Co Initiates Coverage on Targacept (TRGT) with a Hold

